Abstract 2142P
Background
The improvement in cancer survival, allows for higher ICU admission ratios. A pilot program in our center instituted weekly meetings between ICU and Oncology aimed at determining the appropriate level of care for patients admitted in Oncology. Objective: establish which factors predict decision-making regarding the level of care and admission to the ICU and benefit of intensive care.
Methods
Single-center prospective observational study. Recruitment between September-2021 and July-2022. Statistical analysis: descriptive study, multivariate logistic regression for decision of admission in ICU. We performed a second subsequent analysis with the paired propensity score matching technique. Survival analysis: Kaplan-Meier (KM) curves and log-Rank test. Significance level: p ≤ 0.05.
Results
411 patients. 60.3% male; median age: 64 years. Most prevalent tumor: lung (26.3%). Stage IV: 72.5%. The most common reason for admission in Oncology: infectious pathology (33.8%). 54.7% were considered ICU candidates, while only 17 patients (4.1%) finally required intensive care. In a multivariate logistic regression model, ECOG 0-1 (OR 2.7; IC95%: 1.6-4.5), absence of peritoneal carcinomatosis (OR 4.5; IC95%: 2.0-9.9), and intentionality of treatment (adjuvant, neoadjuvant or first-line) (OR 5.4; IC 95%: 3.1-9.5) predicted decision of admission to the ICU. Age > 65 years (OR 0.35; IC 95%: 0.2-0.6) and poor symptom control as cause of admission in Oncology (OR 0.16; 95%: 0.03-0.93) were negative factors for ICU admission. By means of paired propensity analysis (Nearest-neighbor model), the sample was reduced to 172 patients and there was only statistical significance in the univariate analysis for intentionality of treatment and for treatment with immunotherapy (IT). After a median follow-up of 4 months, median survival was significantly different (p< 0.05) for patients who were not ICU candidates (2.5 months), patients who were admitted to the ICU (10 months) and patients who were ICU candidates but did not require admission (12.5 months).
Conclusions
Multidisciplinary decision-making may contribute to individualize the level of intensive care for Oncology patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
F. Ayala de la Pena
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Advisory Board: Leo Pharma, Sanofi, Lundbeck, Angelini. All other authors have declared no conflicts of interest.
Resources from the same session
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07